Autres langues MiMedx Group, Inc.

Actions

MDXG

US6024961012

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
6,245 ^USD	-2,88 %		+1,38 %	-28,79 %

27/03	MiMedx Group déclare que la FDA confirme qu'Axiofill ne répond pas aux normes réglementaires pour les produits à base de tissus	MT
27/03	MiMedx Group, Inc. fait le point sur la demande de désignation (RFD) d'AXIOFILL auprès de la FDA	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30	16/04
MIMEDX Provides Update on AXIOFILL Request for Designation from FDA	28/03
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024	27/03
MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products	27/03
MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit	27/03
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA	27/03
MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation from FDA	27/03
MiMedx Group to Buy Distribution Rights for TELA Bio's Wound Care Product	20/03
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing	20/03
MiMedx Launches E-Commerce Platform	13/03
MIMEDX Introduces E-Commerce and Account Management Platform	13/03
Mimedx Introduces E-Commerce and Account Management Platform	13/03
MIMEDX Announces Appointment of Two New Independent Directors	04/03
MiMedx Group, Inc. Announces Appointment of New Independent Directors	04/03
Spectral AI Names Peter Carlson Chief Executive Officer; Reaffirms 2024 Preliminary Revenue Guidance	01/03
MiMedx: Q4 Earnings Snapshot	28/02
Earnings Flash (MDXG) MIMEDX GROUP Posts Q4 Revenue $86.8M, vs. Street Est of $85.2M	28/02
Earnings Flash (MDXG) MIMEDX GROUP Reports Q4 EPS $0.04, vs. Street Est of $0.06	28/02
MiMedx Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results	28/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues MiMedx Group, Inc.

Actions

MDXG

US6024961012

Autres langues

Filtres